Taken together, these results indicate that inhibition of the pyrimidine synthesis pathway by targeting the β-Catenin/CBP signaling nodule represents a viable therapeutic option to treat TMPRSS2-ERG/GOF p53 mutant-positive PCa. The gene discussed is CREBBP; the disease is posterior cortical atrophy.